Dr Joshua Funder joined GBS in 2004 and has more than 17 years experience in biotechnology research, management and venture investing. Before joining GBS Joshua worked in corporate strategy and development at Infinity Pharmaceuticals in Boston and the Boston Consulting Group in San Francisco. In addition he worked with the Clinton Foundation HIV/AIDS Initiative to successfully negotiate reduced prices for anti-retrovirals and initiate pharmaceutical supplies across eastern and southern Africa. Joshua has experience as founder, director and chairman of biotechnology companies in Australia and the US and brings extensive experience of international venture syndication. He served as interim CEO of Proacta Inc following GBS investment and is on the board of directors of GBS portfolio companies Spinifex Pharmaceuticals Pty Ltd, Pathway Therapeutics Inc, Euthymics Inc. and Celladon Inc. Joshua was director of GBS investee company Peplin Inc (ASX:PLI) which won the AVCAL award for the best early stage investment in 2010.
Joshua earned his Bachelor of Science (Honours) and Bachelor of Laws (Honours) degrees at Melbourne University and his Master of Laws degree at the London School of Economics. He holds a D.Phil in intellectual property for biotechnology from Oxford University where he studied as a Rhodes Scholar.
Joshua Funder's visit to New Zealand is supported by the US Embassy.